［1］Tuynman J B, Yao H W, Moolenaar L R, et al. Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR Ⅲ): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial［J］. Lancet Gastroenterol Hepatol, 2026, 11(5): 355－366.
［2］张忠涛, 杨盈赤. 从TME、TSME及CME看结直肠癌规范化外科治疗［J］. 中国实用外科杂志, 2012, 32(9): 728－730.
［3］杨盈赤, 姚宏伟, 张忠涛. 从TaTME发展看直肠癌微创外科治疗进步［J］. 中国实用外科杂志, 2019, 39(9): 988－990.
［4］张鹏, 张忠涛. 国际减重及代谢外科发展趋势和临床研究热点［J］. 中国实用外科杂志, 2020, 40(4): 408－412.
［5］张忠涛, 张鹏. 中国腹腔镜减重代谢手术20年回顾与展望［J］. 中华普外科手术学杂志: 电子版, 2021, 15(6): 591－597.
［6］李梦伊, 王桂琦, 于卫华, 等. 大中华减重与代谢手术数据库2024年度报告［J］. 中国实用外科杂志, 2025, 45(5): 538－552.
［7］Yang Z Y, Gao J L, Zheng J Y, et al. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study［J］. Signal Transduct Target Ther, 2024, 9(1): 56.
［8］Yang Y C, Pang K, Lin G L, et al. Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial［J］. Nat Med, 2025, 31(2): 449－456.
［9］Yang Z Y, Ma J X, Han J G, et al. Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer［J］. Med, 2024, 5(10): 1293－1306.e4.
［10］Gao J L, Gu X D, Pang M H, et al. Risk factors for anastomotic leak and postoperative morbidity after right hemicolectomy for colon cancer:results from a prospective,multi-centre, snapshot study in China［J］. Br J Surg, 2024, 111(1): znad316.
［11］Pang K, Yang Y, Zhao P F, et al. Adding immune checkpoint blockade to neoadjuvant chemoradiation in locally advanced rectal cancer［J］. Br J Surg, 2022, 109(11): 1178－1179.
［12］Sun L T, Gao J L, Wu G C, et al. Perfusion outcomes with near-infrared indocyanine green imaging system in laparoscopic total mesorectal excision for mid-rectal or low-rectal cancer (POSTER): a study protocol［J］. BMJ Open, 2024, 14(5): e079858.
［13］Sun G Y, Jin H, Zhang C P, et al. OX40 regulates both innate and adaptive immunity and promotes nonalcoholic steatohepatitis［J］. Cell Rep, 2018, 25(13): 3786－3799.e4.
［14］Sun G Y, Zhao X Y, Li M Y, et al. CD4 derived double negative T cells prevent the development and progression of nonalcoholic steatohepatitis［J］. Nat Commun, 2021, 12(1): 650.
［15］Liu S S, Ji Y, Wei L Y, et al. Crotonylation of IDH1 alleviates MASLD progression by enhancing the TCA cycle［J］. Nat Commun, 2025, 16(1): 7961.
［16］Li M Y, Zeng N, Yang L, et al. Histological response and hepatic steatosis changes in nonalcoholic fatty liver disease after bariatric surgery:results from the base-NAFLD Cohort［J］. Int J Surg, 2025, 111(11): 8037－8049.
［17］Yang Z Y, Xia F, Li J, et al. Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer［J/OL］. Gut, 2026: gutjnl-2025-336979. (2026-03-04)［2026-04-23］. https://pubmed.ncbi.nlm.nih.gov/41748160/.
|
